DBV Technologies SA
PAR:DBV

Watchlist Manager
DBV Technologies SA Logo
DBV Technologies SA
PAR:DBV
Watchlist
Price: 2.27 EUR -0.22% Market Closed
Market Cap: 408.2m EUR

DBV Technologies SA
Other Long-Term Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

DBV Technologies SA
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
DBV Technologies SA
PAR:DBV
Other Long-Term Assets
-$1k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Other Long-Term Assets
€16.6m
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-1%
Nanobiotix SA
PAR:NANO
Other Long-Term Assets
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Other Long-Term Assets
€2.4m
CAGR 3-Years
15%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Other Long-Term Assets
$16.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Other Long-Term Assets
€1.1m
CAGR 3-Years
-38%
CAGR 5-Years
-36%
CAGR 10-Years
7%
No Stocks Found

DBV Technologies SA
Glance View

Market Cap
408.2m EUR
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBV Intrinsic Value
11.42 EUR
Undervaluation 80%
Intrinsic Value
Price

See Also

What is DBV Technologies SA's Other Long-Term Assets?
Other Long-Term Assets
-1k USD

Based on the financial report for Jun 30, 2025, DBV Technologies SA's Other Long-Term Assets amounts to -1k USD.

Back to Top